Kornimate/medical-research-clean huggingface dataset:
drug sensitivity of hydrothorax and ascite organoids from breast cancer

Conditions: Breast Cancer Metastatic; Hydrothorax; Ascites; Organoids; Drug Evaluation

Summary: malignant hydrothorax and ascitic fluid in advanced breast cancer often arise from metastasis to the lungs, pleura, or liver. patients with this condition experience rapid disease progression and multidrug resistance, facing limited treatment options. clinical guidelines offer various therapies based on molecular subtypes; however, their effectiveness can be hindered by prior treatments, patient health, and tumor evolution. current evaluations of treatment efficacy typically take two cycles, delaying the recognition of ineffective therapies and resulting in unnecessary side effects and costs. organoid models present a promising solution, accurately replicating tumor structure and cellular diversity compared to traditional methods. these patient-derived models facilitate improved drug sensitivity testing, leading to more personalized treatment plans. in this study, 90 patients diagnosed with metastatic breast cancer accompanied by hydrothorax and ascitic fluid will be recruited. patient-derived organoids will be used to assess the sensitivity of chemotherapy regimens, including doxorubicin, carboplatin, cyclophosphamide, and paclitaxel, along with targeted therapies such as herceptin and pertuzumab.

90 metastatic breast cancer patients with hydrothorax and ascitic fluid will be recruited. baseline data, including medical history, ultrasound, and mri records, will be collected both before and after two cycles of chemotherapy. tumor samples from hydrothorax and ascitic fluid will be obtained and cultured to generate patient-derived organoids (pdos). these pdos will then be exposed to standard chemotherapeutic drugs used in breast cancer treatment. organoid growth will be monitored post-treatment, and dose-response curves will be generated to assess drug sensitivity. to evaluate clinical outcomes, the recist criteria will be applied to measure tumor response in patients. correlation analysis will be performed to determine the consistency between the treatment responses observed in the pdo models and the actual clinical outcomes of the patients.

Eligibility criteria:
inclusion criteria: 1. signed informed consent form and willingness to participate in the clinical study. 2. patients aged between 18 and 70 years old. 3. confirmed metastatic breast cancer patients with hydrothorax and ascite fluid, which was verified to contain tumor cells by lab. 4. ecog performance status score of 0-1. 5. no significant abnormalities in liver and kidney function (bil \<1.5-fold upper limit of normal (uln)；alt\<2.5×uln; ast\<2.5×uln；crea≤1×uln). exclusion criteria: 1.patients not suitable for chemotherapy and target therapy
a study of olezarsen (isis 678354) in participants with hypertriglyceridemia and atherosclerotic cardiovascular disease, or with severe hypertriglyceridemia

Conditions: Hypertriglyceridemia; Cardiovascular Diseases; Atherosclerosis

Summary: the purpose of the study is to evaluate the effect of olezarsen on percent change in fasting triglyceride (tg) levels compared to placebo in participants with hypertriglyceridemia and atherosclerotic cardiovascular disease, or with severe hypertriglyceridemia.

this is a phase 3, multi-center, placebo-controlled study in approximately 1475 participants with hypertriglyceridemia and atherosclerotic cardiovascular disease. the study consists of 3 periods: 1) screening period: week -12 to week -1 (up to 12 weeks); 2) treatment period up to week 53; and 3) post-treatment follow-up period: week 54 to week 66 (13 weeks). participants enrolled will receive olezarsen or placebo once every 4 weeks during the 53-week treatment period. the screening period was extended with no impact to overall study timelines. a coronary computed tomographic angiography (cta) sub study will be performed to assess whether triglyceride lowering through inhibition of apoc-iii protein synthesis may reduce coronary plaque progression.

Eligibility criteria:
inclusion criteria: * participants must fall into 1 of the following groups (a or b): a. hypertriglyceridemia with fasting tg ≥200 mg/dl (2.26 millimoles per liter \[mmol/l\]) and \<500 mg/dl (5.65 mmol/l) with either * clinical diagnosis of atherosclerotic cardiovascular disease (ascvd) or * at increased risk for ascvd b. severe hypertriglyceridemia with fasting tg ≥500 mg/dl (5.65 mmol/l) * participants should be on standard of care (soc) lipid-lowering medications per local guidelines. lipid-lowering medications should be optimized and stabilized for at least 4 weeks prior to screening to minimize changes in these medications during the study. exclusion criteria: * hemoglobin a1c (hba1c) ≥ 9.5% at screening * alanine aminotransferase or aspartate aminotransferase \> 3.0 × upper limit of normal * total bilirubin \> 1.5 upper limit of normal unless due to gilbert's syndrome * estimated gfr \< 30 ml/min/1.73 m\^2 note: other inclusion/exclusion criteria may apply.

Keywords: isis 678354 olezarsen
postprandial effects of a hallucinatory meal on appetite regulation

Conditions: Change in Subjective Appetite Score (VAS)

Summary: several and complex mechanisms are involved in the regulation of appetite and food intake in humans. by means of rapid hypnosis techniques, it is possible to induce some individuals to hallucinate a meal. the same meal (breakfast) is administered as i) a real meal and ii) is evoked as a hallucination under hypnosis in healthy postmenopausal women. the aim of this pilot randomized-controlled cross-over trial is to assess appetite sensation and the blood levels of the appetite-related hormones in the participants.

the regulation of appetite is crucial to control food intake and consequently body weight. hypnosis has been successfully used to modulate gastrointestinal functions, by imagining eating food. in the present pilot trial, the investigators search to investigate the effects a hallucinatory meal by hypnosis on subjective appetite and appetite hormone blood levels. hence, two different breakfast meals are randomly administered to eight healthy postmenopausal women, in a crossover design, consisting of i) a hallucinatory breakfast meal (hb) and ii) a real breakfast meal (rb). on each test day, participants undergo baseline measurements, including appetite sensation and blood sample, then the test meal is hallucinated or served. subjective appetite is assessed each 30 minutes for 4 hours and half, while blood samples are taken at 20', 60', 90' and 180 minutes. at the end of each session, participants are instructed to fill in a food record for the following 3-days.

Eligibility criteria:
inclusion criteria: * female gender, * ability to develop a visual hallucination during hypnosis, * body mass index (bmi) range 20-27 kg/m2, * menopausal status exclusion criteria: * smoking, * breakfast skipping, * current intake of any supplements, * current use of any drug, * presence of any pathological conditions, including mental and eating disorders, * any alimentary restrictions or specific diets, * allergies or food intolerances or dislikes of the offered breakfast-meal, * being a shift or night workers, * unable to give a written informed consent
using an internet study to improve adherence for psoriasis patients

Conditions: Psoriasis

Summary: to evaluate whether participation in an internet-based intervention helps improve short-term and long-term psoriasis treatment outcomes, in particular, adherence.

an investigator-blinded, prospective study of subjects with mild to moderate psoriasis will be conducted. forty subjects ages 18 years and older will be enrolled.the internet-based survey will be piloted to evaluate its effect on adherence to topical psoriasis medication. subjects randomized in a 1:1 ratio to the internet-survey group will log their impression of the state of their psoriasis on a weekly basis. subjects in both the intervention and control groups will receive standard-of-care topical fluocinonide 0.05% ointment to be applied to affected areas on the skin twice daily. adherence to fluocinonide will be assessed using medication event monitoring system (mems®) caps, electronic monitors affixed to the medication containers. investigators and subjects will be blinded to the adherence data until the final (month 12) treatment visit.

Eligibility criteria:
inclusion criteria: * any male or female 18 years or older of age with a diagnosis of mild to moderate psoriasis by a dermatologist will be eligible for participation. * less than 20% of body surface involvement for psoriasis. * subject is capable of understanding and willing to provide a signed and dated written voluntary informed consent before any protocol specific procedures are performed. * the subject is able to complete the study and comply with study instructions, including attending all study visits. * in general good health with no other skin disease, disease state or physical condition which would impair evaluation of psoriasis or which would increase health risk by study participation exclusion criteria: * individuals younger than 18 years of age. * known allergy or sensitivity to topical fluocinonide. * inability to complete all study-related visits, or inability to complete the internet survey due to inadequate internet access. * introduction of any other prescription medication, topical or systemic, for psoriasis while participating in the study. subjects who are on systemic anti-inflammatory treatments for psoriasis must be on a stable dose for at least 3 months prior to enrollment. * any skin condition or disease that may require concurrent therapy or may confound evaluations * current enrollment in any research study involving an investigational drug
usability study of the fempulse system

Conditions: Overactive Bladder

Summary: the objective of the study is to demonstrate that the fempulse system can be used as indicated in the instructions for use (ifu), as applicable.


Eligibility criteria:
key inclusion criteria: * females, defined as a person with a uterus and cervix, ≥21 years old, with a diagnosis of oab and symptoms for more than 6 months, as confirmed by a physician * able to read, comprehend, and reliably provide informed consent and study-related information. * willing and able to comply with study required procedures and visits (e.g., maintaining consistent medication use, fluid intake, diary completion). * has adequate cognitive and manual capabilities to operate the fempulse system and other components (e.g., mobile app) as assessed by the investigator. key exclusion criteria: * currently pregnant, was pregnant in the past 12 months or intending to conceive during the study period. * plans to begin other oab therapies or otherwise change their existing therapy regimen during the study period. * not an appropriate study candidate as determined by investigator.

Keywords: neuromodulation
hepatocellular cancer (hcc) screening in zhongshan city

Conditions: Liver Neoplasms

Summary: all participants in the selected communities will be tested for hbsag by using serum samples. among those who are positive for hbsag, further clinical work-ups including afp test and ultrasonography for liver exam will be performed. high risk group will be selected according to the definition. hcc diagnosis will be determined according to imaging and/or biopsy result. repeated check-ups will be performed in 6-months among hbsag positive group and 3-years among hbsag negative group. all subjects in the control arm (control communities) will be followed by record linkage to cancer register and population register.

sample selection * select communities of 70,000 to 120,000 populations in zhongshan city as the investigators' fields. * divide them into screening group and control group according to the areas of administration participants recruitment - subjects voluntarily attend this screening study informed consent - informed consent forms will be collected at the recruitment. questionnaires - face-to-face interviews are conducted by well-trained investigators serological tests * each blood samples will be tested for the surface antigen of the hepatitis b virus (hbsag). * among those who are positive for hbsag, further clinical work-ups including alpha-fetoprotein(afp) test and ultrasonography for liver exam will be performed and high risk group will be selected according to the definition. * hcc diagnosis will be determined according to imaging and/or biopsy result. * the rest of the blood samples will be stored at the biobank of zhongshan people's hospital. follow up * the cohort will follow up according to the screening protocol. briefly, repeated check-ups will be performed in 6-months among hbsag positive group and 3-years among hbsag negative group. * all subjects in the control arm (control communities) will be followed by record linkage to cancer register and population register.

Eligibility criteria:
inclusion criteria: * residences in zhongshan city * have no medical records of hepatocellular cancer * ecog 0-2 * provide written informed consent forms * have a good physical and psychological condition exclusion criteria: * have severe cardiovascular or kidney disease * have medical records of hepatocellular cancer

Keywords: screening hepatocellular cancer biomarker mortality rate
efficacy of cap-assisted chromoendoscopy as a screening test for colorectal neoplasm using web-based research network

Conditions: Colorectal Neoplasm

Summary: the investigators plan to conduct a multi-center, randomized controlled trial to investigate the efficacy of cap-assisted chromoendoscopy as a screening test for detection of colorectal polyp. this study will be performed using web-based research network, e-velos in korea.

various endoscopic tools have been tried to reduce polyp missing rate which has been reported to be 20-25%. transparent cap-assisted colonoscopy has been suggested to improve visualization of the lesion that are difficult to access, such as tangentially located lesions and those located within a limited luminal space. chromoendoscopy with indigocarmine spraying was reported to increases the detection rates of polyp, especially in right colon and rectum. however, there also have been mixed results regarding polyp detection rates of the endoscopic methods. moreover, there is no data regarding the impact of the screening tools on longterm recurrence rate of colorectal polyp. therefore, in this study, we intend to perform a multi-center, randomized controlled trial to investigate the efficacy of cap-assisted chromoendoscopy as a screening test for detection of colorectal polyps. this study will be performed using web-based research network, e-velos in korea.

Eligibility criteria:
inclusion criteria: * all asymptomatic colonoscopic examinees exclusion criteria: * familial history of hereditary colorectal cancer * history of colorectal cancer * patients had received colonoscopy examination before * familial or past history of fap(familiar adenomatous polyposis) * colonic polyposis syndrome * prior colonic resection of any part of the colon * allergy to indigo carmine * inflammatory bowel disease * pregnancy * inability to provide informed consent

Keywords: colorectal neoplasm colonoscopy chromoendoscopy cap-assisted colonoscopy
a phase 1，open-label study of bpi-421286 in subjects with advanced solid tumors

Conditions: Malignant Neoplasms; Metastatic Cancer

Summary: evaluate the safety and tolerability of bpi-421286 in adult subjects with advanced solid tumors. estimate the maximum tolerated dose (mtd) and/or a recommended phase 2 dose (rp2d) in adult subjects with advanced solid tumors.


Eligibility criteria:
inclusion criteria: * pathologically documented, locally-advanced or metastatic malignancy * standard treatment is not available or patient declines * adequate organ function exclusion criteria: * active brain metastases from non-brain tumors. * gastrointestinal (gi) tract disease causing the inability to take oral medication. * other protocol specified criteria

Keywords: antineoplastic agents kras nsclc colorectal cancer pancreatic cancer kras g12c
trial of continuous versus interrupted feeding for intubated intensive care unit patients

Conditions: Malnutrition

Summary: surgical patients fed up until the point of surgery will have safe delivery of more calories compared to a group whose feeding is held at midnight prior to surgery.

nutrition is essential for healing and recovery from illness. tube feeds are the standard care for patients with prolonged stays in the intensive care unit (icu) who cannot eat food on their own. tube feeding means that a tube has been placed in a patient's stomach or small intestine to provide nutrition. when a patient is scheduled for an elective surgery, he/she usually has nothing to eat after midnight prior to the operation. a fasting period before surgery is done to avoid possible side effects during the placement of a breathing tube. having an empty stomach is thought to decrease the chances of vomiting or aspiration while a breathing tube is placed. (aspiration occurs when a substance, such as food provided by a tube feed, enters the airway.) however, some patients already have a breathing tube in place. the investigators do not know which is better for patients who already have a breathing tube in place: continuing feedings up until surgery or stopping them the night before. the investigators hypothesize intubated surgical patients randomized to a protocol of feeding up until the point of surgery will have the safe delivery of more calories as compared to a group whose feeding is held at midnight prior to surgery.

Eligibility criteria:
inclusion criteria: * intubated with planned visit to the or * admitted to an icu at ohsu * receiving enteral nutrition or plan to start enteral nutrition exclusion criteria: * age less than 18 years * unable to obtain consent from patient or arr

Keywords: enteral nutrition enteral feeding nasogastric tubes gastrostomy tubes jejunostomy tubes
the effect of saae on ventricular remodeling in pa patients

Conditions: Primary Aldosteronism

Summary: the study aims to assess the effect of superselective adrenal arterial embolization on ventricular remodeling in primary aldosteronism without lateralized aldosterone secretion by comparing it with spironolactone therapy.

after being informed about the study and potential risks,all patients giving written informedconsent will undergo a 2-week screening period to determine eligibility for study entry.atweek 0,patients who meet the eligibility requirements will be randomized in a 1:1 ratio to superselective adrenal arterial embolization group or spironolactone therapy group.

Eligibility criteria:
inclusion criteria: * (1) age 18-60 years old, regardless of gender; * (2) blood pressure conditions meet one of the following: 1) office blood pressure ≥ 140/90mmhg; 2) ambulatory blood pressure monitoring whole day blood pressure \> 130/80 mmhg or daytime blood pressure \> 135/85 mmhg; * (3) after strict drug elution, it met the diagnostic criteria of primary aldosteronism, and bilateral primary aldosteronism was confirmed by adrenal venous sampling; * (4) no surgical intent or contraindication to surgery and willing to undergo pharmacological treatment or percutaneous superselective adrenal artery embolization; * (5) the patient or his/her legal representative shall sign the written informed consent approved by the ethics committee before the screening. exclusion criteria: * (1) primary hypertension or secondary hypertension with other causes; * (2) a woman who is pregnant or lactating, or has a birth plan for the next year; * (3) there are serious organic diseases, especially liver and kidney dysfunction(egfr\<45 ml/min/1.73 m2); * (4) severe allergy to contrast medium; * (5) other serious organic diseases, life expectancy \< 12 months; * (6) adrenal ct showed adenoma.; * (7) patients are enrolled or want to participate in other clinical studies. during the enrollment study, the results of this study will be affected.

Keywords: primary aldosteronism selective adrenal artery embolization bilateral primary aldosteronism nondominant lateral secretory primary aldosteronism ventricular remodeling
clinicopathologic and ancillary testing of primary clear cell carcinoma of the cervix

Conditions: Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type

Summary: this study aims to provide a comprehensive report on clinicopathologic features, immunohistochemical/biomarker testing and molecular profile of cervical clear cell carcinoma. this study may help researchers learn more about the molecular profile of cervical clear cell carcinoma.

primary objective: i. to perform a retrospective clinicopathologic study on patients diagnosed and treated for clear cell carcinoma of the cervix at m d anderson cancer center (mdacc) and to delineate the immunohistochemical and molecular profile of these cases. outline: patients' medical records are reviewed retrospectively, and archival tumor tissue analyzed by immunohistochemistry and next generation sequencing.

Eligibility criteria:
inclusion criteria: * patients diagnosed with clear cell carcinoma of the cervix at mdacc
impact of intravenous methylprednisolone treatment on blood pressure

Conditions: Graves Disease; Graves Ophthalmopathy; Hypertension; Blood Pressure; Heart Failure

Summary: hypertension is common side effect of cushing syndrome (cs): in patients with endogenous cs and those treated with glucocorticosteroids (gcs). the impact of the intravenous gcs therapy on blood pressure (bp) remains unclear. according to the european group on graves' orbitopathy (eugogo), patients with active, severely symptomatic and sight-threatening graves' orbitopathy (go) should be treated with high dose intravenous methylprednisolone (ivmp) pulses. there are, however, reports of fatal side effects that may be associated with this therapy (e.g.: pulmonary embolism, myocardial infarction, severe cerebrovascular events, acute liver damage and sudden death). for this reason, the cumulative dose of ivmp should not exceed 8 g within each treatment course, and pulses should not be given on consecutive or alternate days, except for the case of dysthyroid optic neuropathy. a consensus on the monitoring of patients during and after ivmp pulse administration is not yet established. what is more, there is lack of paper regarding pattern of blood pressure at various time points during and after ivgcs administration. thus, the investigators decided to evaluate acute changes of n-terminal pro-brain natriuretic peptide (nt-probnp) as a marker of hemodynamic stress and to monitor bp before, during and after ivmp pulse administration. all of patients were treated routinely according to eugogo recommendations with standard doses of methylprednisolone with standard recommended schedule. inclusion criterion for the therapy was according to eugogo guidelines active, moderate-to-severe and active go (12 pulses of ivmp 6x0.5g followed by 6x0.25g every week).

laboratory tests such as nt-probnp, troponin i (tni) and high - sensitivity c - reactive protein (hs-crp) were performed before, 24 h and 48 h after ivmp during the following pulses: 1st, 6th and 12th. patients underwent echocardiographic examination before 1st and after 12th pulse. 48-hours ambulatory blood pressure monitoring (abpm) (for 24 hours before and 24 hours after ivmp) was done during the following pulses: 1st, 6th and 12th.

Eligibility criteria:
inclusion criteria: * active, moderate-to-severe go according to eugogo classification * euthyroidism * completion of at least first six ivmp pulses. exclusion criteria: * cardiovascular morbidity (such as chronic heart failure and/or coronary heart disease) * uncontrolled hypertension (defined as systolic blood pressure (sbp) more than 140 mmhg and/or diastolic blood pressure (dbp) more than 90 mmhg) * contraindications to ivmp therapy * previous gcs treatment in the last 6 months.

Keywords: graves' disease graves' ophthalmopathy hypertension blood pressure methylprednisolone glucocorticoids